Losoxantrone is a DNA intercalator that was developed with the potential to replace anthracyclines. Losoxantrone is also a bioreductive drugs. In phase II trials, losoxantrone demonstrated a partial bioactive compound response rate of 25%, response in measurable disease sites in 22%, and improvement in clinical symptoms in one-third of patients. References: Liang H, Wu X, Guziec LJ, Guziec FS Jr, Larson KK, Lang J, Yalowich JC, Hasinoff BB. A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone. J Chem Inf Model. 2006 Jul-Aug;46(4):1827-35. PubMed PMID: 16859314.

纯度：≥98%

CAS：88303-60-0